Neither a prescription nor an outsourcing-facility registration establishes that a particular proposed preparation satisfies every applicable condition.
Affected arrangements: Proposed compounded preparations; clinic-stock and patient-specific arrangements.
Start with the arrangement
FDA describes different conditions for section 503A compounding and section 503B outsourcing facilities. The former generally concerns patient-specific compounding; the latter involves registered facilities subject to current good manufacturing practice requirements. This distinction is an initial classification, not an approval result. Ask the supplier to name the legal entity, physical facility, medicine, ingredients, presentation and intended destination.
Keep three questions separate
The procurement file should distinguish product status, facility evidence and the legal basis asserted for the specific supply. An active facility record answers an identity question. It cannot alone answer whether a proposed GLP-1 preparation, stock arrangement or destination is permissible. Patient-specific dispensing is an attribute of the workflow; it should not be treated as a standalone permission to compound.
Build the review file
Create one row per proposed arrangement. Record the pathway asserted by the supplier, source document, date, preparation, destination states and questions requiring counsel. Attach the supplier's actual statement rather than converting it into an editorial conclusion. If the rationale refers to a shortage or an enforcement-discretion period, require the exact dated authority and its present relevance to be checked.
Name the next owner
Operations can collect evidence and map responsibilities. Qualified legal and clinical reviewers resolve questions within their scope. Keep the result marked assessment incomplete while material questions remain. A complete document folder is not an authorisation, and a lower commercial quote should not change the review gate.
Questions to take forward
- Which specific preparation and supply model are proposed?
- What written basis supports this arrangement in every destination state?
- Who will review that basis before a commitment?
Primary sources & evidence limits
FDA: Compounding questions and answers ↗Publication date not confirmed · Accessed 2026-11-17FDA: GLP-1 compounding policies and dated shortage milestones ↗Latest dated update retrieved: 1 April 2026 · Accessed 2026-11-17FDA: Outsourcing facility registration questions and answers ↗Publication date not confirmed · Accessed 2026-11-17Primary-source links were opened or retrieved on 17 November 2026. This date records source access, not legal or clinical review. Procurement checklists and commercial models are editorial methods. No live supplier, licence, coverage or capacity verification has been performed.